Dupilumab Offers ' Clinically Meaningful ' Improvements in PN Dupilumab Offers ' Clinically Meaningful ' Improvements in PN

The monoclonal antibody dupilumab markedly reduces itch and the number of skin lesions in previously treated patients with severe prurigo nodularis, suggest results from a phase 2 trial.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news